Financials VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:49:09 2024-12-10 pm EST			5-day change	1st Jan Change
2.700 ^USD	-1.82%		-5.27%	+15.06%

Nov. 18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
Nov. 07	Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000	MT

Projected Income Statement: VYNE Therapeutics Inc.

income-statement-evolution-chart VYNE-THERAPEUTICS-INC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	0.443	20.99	14.76	0.477	0.424	0.55	0.25	0.3
Change	-	4,638.83%	-29.71%	-96.77%	-11.11%	29.72%	-54.55%	20%
EBITDA ¹	-	-	-	-	-29.26	-45.5	-54.4	-62
Change	-	-	-	-	-	-55.51%	-19.56%	-13.97%
EBIT ¹	-95.87	-252.5	-68.03	-34.3	-29.26	-44.85	-55.25	-61.55
Change	-	163.42%	-73.06%	-49.59%	-14.69%	-53.29%	-23.19%	-11.4%
Interest Paid	-0.921	-4.39	-5.61	-	-	-	-	-
Earnings before Tax (EBT) ¹	-95.35	-255.8	-73.78	-33.93	-27.87	-40.45	-53.3	-61.35
Change	-	168.29%	-71.16%	-54.01%	-17.86%	-45.13%	-31.77%	-15.1%
Net income ¹	-95.18	-255.6	-73.33	-23.21	-28.45	-40.45	-53.3	-61.35
Change	-	168.52%	-71.31%	-68.35%	22.59%	-42.17%	-31.77%	-15.1%
Announcement Date	3/12/20	3/4/21	3/17/22	3/9/23	2/29/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	0.135	1.75	11.69	3.269	4.286	4.119	4.258	4.086	2.292	0.178	0.126	0.167	0.006	0.099	0.135	0.114	0.076	0.098	0.198	0.121	0.14	0.1	0.1	0.1	0.1
Change	-	1,196.3%	567.89%	-72.03%	31.11%	-3.9%	3.37%	-4.04%	-43.91%	-92.23%	-29.21%	32.54%	-96.41%	1,550%	36.36%	-15.56%	-33.33%	28.95%	102.04%	-38.89%	15.7%	-28.57%	0%	0%	0%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.234	-6.832	-7.38	-10.4	-13.09	-14.7	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.59%	8.02%	40.87%	25.92%	-12.29%	100%	-	-	-
EBIT ¹	-37.43	-39.89	-167.2	-23.49	-21.99	-19.43	-16.88	-17.78	-12.04	-8.691	-8.287	-9.333	-7.984	-5.875	-10.32	-	-	-	-	-	-13.4	-13.6	-13.9	-14.2	-14.5
Change	-	6.57%	319.11%	-85.95%	-6.39%	-11.63%	-13.13%	5.31%	-32.25%	-27.84%	-4.65%	12.62%	-14.45%	-26.42%	75.63%	-100%	-	-	-	-	-	-1.49%	-2.21%	-2.16%	-2.11%
Charge d'intérêts	-0.592	-0.344	-0.522	-1.226	-1.161	-1.119	-1.074	-3.474	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-37.82	-40.23	-167.7	-24.71	-23.18	-20.55	-19.92	-21.28	-12.02	-8.694	-8.235	-9.255	-7.748	-5.612	-10.04	-6.071	-6.152	-	-9.395	-12.16	-12.65	-12.7	-13	-13.2	-13.5
Change	-	6.38%	316.82%	-85.26%	-6.2%	-11.35%	-3.05%	6.83%	-43.54%	-27.66%	-5.28%	12.39%	-16.28%	-27.57%	78.87%	-39.52%	1.33%	-100%	-	29.4%	-4.06%	-0.4%	-2.36%	-1.54%	-2.27%
Net income ¹	-37.82	-40.23	-167.4	-24.71	-23.18	-20.55	-19.92	-21.28	-11.57	4.67	-8.476	-9.459	-9.945	-5.622	-10.06	-6.584	-6.188	-6.249	-9.406	-12.16	-12.65	-12.69	-12.96	-13.24	-13.52
Change	-	6.38%	316.18%	-85.24%	-6.2%	-11.35%	-3.05%	6.83%	-45.64%	-	-	11.6%	5.14%	-43.47%	78.9%	-34.54%	-6.01%	0.99%	50.52%	29.25%	-4.06%	-0.32%	-2.13%	-2.16%	-2.11%
Announcement Date	3/12/20	5/11/20	8/6/20	11/5/20	3/4/21	5/6/21	8/12/21	11/10/21	3/17/22	5/12/22	8/12/22	11/10/22	3/9/23	5/11/23	8/14/23	11/13/23	2/29/24	5/9/24	8/14/24	11/7/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: VYNE Therapeutics Inc.

balance-sheet-analysis-chart VYNE-THERAPEUTICS-INC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	3/12/20	3/4/21	3/17/22	3/9/23	2/29/24	-	-	-

Estimates

Cash Flow Forecast: VYNE Therapeutics Inc.

Fiscal Period: December	2018	2019	2020	2021	2022	2023
CAPEX ¹	0.567	1.058	0.113	-	-	-
Change	-	86.6%	-89.32%	-	-	-
Free Cash Flow (FCF) ¹	-41.77	-40.27	-77.11	-33.05	-11.86	-12.25
Change	-	-3.6%	91.5%	-57.14%	-64.12%	3.25%
Announcement Date	2/28/19	3/12/20	3/4/21	3/17/22	3/14/23	3/1/24

¹USD in Million

Estimates

Forecast Financial Ratios: VYNE Therapeutics Inc.

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-	-	-	-	-	-6,900.47%	-8,272.73%	-21,760%	-20,666.67%
EBIT Margin (%)	-	-21,641.76%	-1,203%	-461.08%	-7,189.73%	-6,900.47%	-8,154.55%	-22,100%	-20,516.67%
EBT Margin (%)	-	-21,524.6%	-1,218.63%	-500.01%	-7,113.63%	-6,573.58%	-7,354.55%	-21,320%	-20,450%
Net margin (%)	-	-21,484.88%	-1,217.4%	-496.98%	-4,865.83%	-6,710.38%	-7,354.55%	-21,320%	-20,450%
FCF margin (%)	-	-16,806.32%	-653.53%	-382.02%	-	-	-	-	-
FCF / Net Income (%)	-	78.22%	53.68%	76.87%	-	-	-	-	-
Profitability
ROA	-50.88%	-64.82%	-69.52%	-52.89%	-39.77%	-26.42%	-	-	-
ROE	-92.25%	-173.43%	-928.19%	-170.28%	-84.81%	-46.4%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	238.83%	0.54%	-	-	-	-	-	-
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-1.42%	-0.08%	-	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-	-141.8	-25.56	-7.28	-2.78	-0.96	-1.13	-1.16
Change	-	-	-	-81.98%	-71.52%	-61.81%	-65.47%	17.71%	2.65%
Nbr of stocks (in thousands)	-	-	2,332	2,973	3,224	13,957	14,751	14,751	14,751
Announcement Date	-	-	3/4/21	3/17/22	3/9/23	2/29/24	-	-	-